FI92556B - Förfarande för framställning av en intravenös farmaceutisk sammansättning - Google Patents

Förfarande för framställning av en intravenös farmaceutisk sammansättning Download PDF

Info

Publication number
FI92556B
FI92556B FI893520A FI893520A FI92556B FI 92556 B FI92556 B FI 92556B FI 893520 A FI893520 A FI 893520A FI 893520 A FI893520 A FI 893520A FI 92556 B FI92556 B FI 92556B
Authority
FI
Finland
Prior art keywords
polyethylene glycol
cyclosporin
composition
process according
compositions
Prior art date
Application number
FI893520A
Other languages
English (en)
Finnish (fi)
Other versions
FI92556C (sv
FI893520A (sv
FI893520A0 (sv
Inventor
Gabor Ambrus
Imre Moravcsik
Istvan Elekes
Tibor Balogh
Lajos Ila
Lajos Siklosi
N E Joszt Eva Tomori
N Ernoe Orb
N E Bok Ny Antonia Jekkel
S Ndor Elek
N E Toth Eva Sarudy
Original Assignee
Biogal Gyogyszergy R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogal Gyogyszergy R filed Critical Biogal Gyogyszergy R
Publication of FI893520A0 publication Critical patent/FI893520A0/sv
Publication of FI893520A publication Critical patent/FI893520A/sv
Application granted granted Critical
Publication of FI92556B publication Critical patent/FI92556B/sv
Publication of FI92556C publication Critical patent/FI92556C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

1. Förfarande för framställning av en intravenös farmaceutisk sammansättning omfattande cyklosporin som aktiv beständsdel, kännetecknat av att man blandar a) 1 viktdel av en eller flera cyklosporiner, b) 8-13 viktdelar av en monoester av en mättad hydroxylerad fettsyra bildad med polyetylenglykol, eller en blandning av sagda monoestrar, och c) 4 - 10 viktdelar av en eller flera mono- eller polyvalenta alkoholer som kan ges intravenöst.
2. Förfarande enligt krav 1, kännetecknat av att säsom cyklosporin används en eller flera cyklosporiner ur gruppen cyklosporin A, cyklosporin C och cyklosporin G.
3. Förfarande enligt krav l, kännetecknat av att man använder en eller flera monoestrar av mättade, hydroxyle-rade C10.22-fettsyror bildade med polyetylenglykol (PEG) med en raolekylvikt pä 600 - 1300.
.* 4. Förfarande enligt krav 1, kännetecknat av att säsom komponent b) används en eller flera monoestrar av mättade, hydroxylerade C14.22-fettsyror bildade med polyetylenglykol (PEG) med en molekylvikt av 750 - 1100.
5. Förfarande enligt krav l, kännetecknat av att säsom komponent b) används en eller flera komponenter ur gruppen bestäende av polyetylenglykol-9-hydroximyristat, polyety-len-glykol-9-hydroxipalmitat och polyetylenglykol-12-hydroxis-tearat.
6. Förfarande enligt krav l, kännetecknat av att säsom komponent b) används polyetylenglykol-660-12-hydroxi- 92556 18 stearat.
7. Förfarande enligt krav 1, kännetecknat av att säsom komponent c) används ett eller flera ämnen ur gruppen bestäende av etylalkohol, propylenglykol och/eller polyetylen-glykol. II
FI893520A 1988-07-21 1989-07-21 Förfarande för framställning av en intravenös farmaceutisk sammansättning FI92556C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU883796A HU201567B (en) 1988-07-21 1988-07-21 Process for production of intravenous medical compositions containing cyclosphorin
HU379688 1988-07-21

Publications (4)

Publication Number Publication Date
FI893520A0 FI893520A0 (sv) 1989-07-21
FI893520A FI893520A (sv) 1990-01-22
FI92556B true FI92556B (sv) 1994-08-31
FI92556C FI92556C (sv) 1994-12-12

Family

ID=10965544

Family Applications (1)

Application Number Title Priority Date Filing Date
FI893520A FI92556C (sv) 1988-07-21 1989-07-21 Förfarande för framställning av en intravenös farmaceutisk sammansättning

Country Status (26)

Country Link
US (1) US5047396A (sv)
JP (1) JPH07116051B2 (sv)
KR (1) KR0137674B1 (sv)
AR (1) AR243382A1 (sv)
AT (1) AT402258B (sv)
AU (1) AU614862B2 (sv)
BE (1) BE1004323A4 (sv)
CA (1) CA1332712C (sv)
CH (1) CH679120A5 (sv)
DD (1) DD283934A5 (sv)
DE (1) DE3924207A1 (sv)
DK (1) DK175540B1 (sv)
FI (1) FI92556C (sv)
FR (1) FR2635265B1 (sv)
GB (1) GB2221157B (sv)
GR (1) GR1002184B (sv)
HU (1) HU201567B (sv)
IL (1) IL91069A (sv)
IT (1) IT1231434B (sv)
LU (1) LU87560A1 (sv)
NL (1) NL194578C (sv)
NO (1) NO175287C (sv)
NZ (1) NZ230036A (sv)
PT (1) PT91246B (sv)
SE (1) SE509174C2 (sv)
ZA (1) ZA895588B (sv)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
ES2098739T3 (es) * 1992-05-13 1997-05-01 Sandoz Ltd Composiciones oftalmicas conteniendo una cyclosporin.
EP0589843B1 (en) 1992-09-25 2001-11-28 Novartis AG Pharmaceutical compositions containing cyclosporins
DE4412201A1 (de) * 1993-04-20 1994-11-10 Rentschler Arzneimittel Neue pharmazeutische Zubereitungen zur oralen Verabreichung enthaltend Cyclosporin
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
RU2158601C2 (ru) * 1994-11-03 2000-11-10 Новартис Аг Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
PL319898A1 (en) * 1995-08-25 1997-09-01 Sangstat Medical Corp Cyclosporines containing compositions for oral administration
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US20050053594A1 (en) * 1995-11-16 2005-03-10 Dario Alessi RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
NZ336900A (en) * 1997-01-30 2001-06-29 Novartis Ag Hard gelatine capsules containing pharmaceutical compositions comprising cyclosporin A and being substantially free of any oil
SI0969856T1 (en) * 1997-03-12 2005-06-30 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
AT408186B (de) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag Wässerige zubereitung von beta-carotin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
FR2826517B1 (fr) * 2001-06-20 2004-03-12 Somfy Dispositif d'alimentation pour store motorise ou similaire
KR100978836B1 (ko) * 2001-10-19 2010-08-30 이소테크니카 인코포레이티드 신규한 시클로스포린 유사체 미세유화액 예비농축물
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
JP4815418B2 (ja) * 2007-10-19 2011-11-16 カヤバ工業株式会社 空圧緩衝器
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
CA3122934A1 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Fusion protein comprising a fragment of cd40 and method of producing same
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3658M (fr) * 1964-02-18 1965-11-02 Michel Marie Andre Guerbet Composition huileuse pour l'injection intravasculaire.
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) * 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
AU534955B2 (en) * 1980-01-23 1984-02-23 Sandoz Ag Cyclosporin a to treat lymphoproliferative disorders
DE3339235A1 (de) * 1983-10-28 1985-05-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von polyurethanen
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
JPH02501389A (ja) * 1987-10-02 1990-05-17 フセソユズニ　カルディオロジチェスキ　ナウチニ　ツェントル　アカデミイ　メディツィンスキフ　ナウク　エスエスエスエル 多発性硬化症及び筋萎縮側索硬化症の治療用薬用製剤
GB8729153D0 (en) * 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US4943560A (en) * 1988-04-06 1990-07-24 Regents Of The University Of Minnesota Solvent system for chronic vascular infusion of hydrophobic drugs
DE3832362A1 (de) * 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
NL8901902A (nl) 1990-02-16
FR2635265B1 (fr) 1995-03-17
AU3884589A (en) 1990-02-01
NZ230036A (en) 1991-02-26
NL194578B (nl) 2002-04-02
IL91069A (en) 1993-07-08
US5047396A (en) 1991-09-10
NO175287B (no) 1994-06-20
CH679120A5 (sv) 1991-12-31
GR890100467A (el) 1990-06-27
FR2635265A1 (fr) 1990-02-16
NO175287C (no) 1994-09-28
SE8902588D0 (sv) 1989-07-21
DE3924207A1 (de) 1990-01-25
NO892995L (no) 1990-01-22
DK175540B1 (da) 2004-11-29
JPH07116051B2 (ja) 1995-12-13
JPH03115227A (ja) 1991-05-16
GB2221157A (en) 1990-01-31
KR0137674B1 (ko) 1998-05-15
KR900001364A (ko) 1990-02-27
DE3924207C2 (sv) 1992-07-09
DK362189D0 (da) 1989-07-21
AT402258B (de) 1997-03-25
DD283934A5 (de) 1990-10-31
FI92556C (sv) 1994-12-12
DK362189A (da) 1990-01-22
FI893520A (sv) 1990-01-22
NL194578C (nl) 2002-08-05
CA1332712C (en) 1994-10-25
FI893520A0 (sv) 1989-07-21
IT1231434B (it) 1991-12-04
GR1002184B (en) 1996-03-12
LU87560A1 (fr) 1991-02-18
ATA176789A (de) 1996-08-15
BE1004323A4 (fr) 1992-11-03
NO892995D0 (no) 1989-07-21
PT91246B (pt) 1995-05-04
GB2221157B (en) 1991-12-18
PT91246A (pt) 1990-02-08
IT8921259A0 (it) 1989-07-21
AR243382A1 (es) 1993-08-31
AU614862B2 (en) 1991-09-12
GB8916679D0 (en) 1989-09-06
SE8902588L (sv) 1990-01-22
ZA895588B (en) 1990-07-25
HUT50851A (en) 1990-03-28
SE509174C2 (sv) 1998-12-14
HU201567B (en) 1990-11-28

Similar Documents

Publication Publication Date Title
FI92556B (sv) Förfarande för framställning av en intravenös farmaceutisk sammansättning
KR100452003B1 (ko) 정맥내주사용라파마이신제형
KR100607391B1 (ko) 시클로덱스트린 및 탁소이드를 함유하는 약제학적 조성물
Doenicke et al. A Comparison of Two Formulations for Etomidate, 2-Hydroxypropyl-$ bT-cyclodextrin (HPCD) and Propylene Glycol
PT633783E (pt) Formulacao de rapamicina para injeccao intravenosa
EP0650729B1 (en) Rapamycin formulations for IV injection
US20150238563A1 (en) Cyclosporine emulsion
JPH07149656A (ja) 経口投与ラパマイシン製剤
Tibell et al. Dissolving intravenous cyclosporin A in a fat emulsion carrier prevents acute renal side effects in the rat
RU2367472C1 (ru) Парентеральное лекарственное средство и способ его получения
CN104274406A (zh) 一种注射用他克莫司脂肪乳剂及其制备方法
JPH07196507A (ja) 静脈注射用ラパマイシン製剤
Pang et al. Lidocaine increases lung uptake of propranolol
BR112013007373B1 (pt) Emulsão de ciclosporina, e, uso de uma emulsão de ciclosporina

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: BIOGAL GYOGYSZERGYAR RT.

PC Transfer of assignment of patent

Owner name: TEVA GYOGYSZERGYAR ZARTKOERUEEN MUEKOEDOE RESZVENY

Free format text: TEVA GYOGYSZERGYAR ZARTKOERUEEN MUEKOEDOE RESZVENYTARSASAG